FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SULAT JAMES R
2. Issuer Name and Ticker or Trading Symbol

Arch Therapeutics, Inc. [ ARTH ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6
3. Date of Earliest Transaction (MM/DD/YYYY)

6/22/2020
(Street)

FRAMINGHAM, MA 01702
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1)6/22/2020  O  454546 A$81818.28 1376813 (2)I (3)See Footnote (3)
Common Stock         370000 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series D Warrant (right to buy) (1)$0.18 6/22/2020  O   454546    6/30/2015 6/30/2020 Common Stock 454546 $0 0 I (3)See Footnote (3)
Series J Warrant (right to buy) (4)$0.25 6/22/2020  P   340910    6/22/2020 6/22/2021 Common Stock 340910 $0 340910 I (3)See Footnote (3)

Explanation of Responses:
(1) Of the Shares purchased, all are from the exercise of Series D Warrants originally issued as part of a private placement that was concluded on July 2, 2015 and originally issued with an exercise price of $0.25. On June 3, 2020, among other items, the exercise price of the Series D Warrants was amended to $0.18.
(2) Excludes (a) 41,666 shares of our Common Stock held by the Brenna Keyes Sulat Irrevocable Trust; and, (b) 41,666 shares of our Common Stock held by the Nathaniel Keyes Sulat Irrevocable Trust. Mr. Sulat is a co-trustee of each of the Trusts along with his wife.
(3) Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries.
(4) Series J Warrants issued upon the exercise of and payment for all Series D warrants.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
SULAT JAMES R
C/O ARCH THERAPEUTICS, INC.
235 WALNUT STREET, SUITE 6
FRAMINGHAM, MA 01702
X



Signatures
/s/ James R. Sulat6/23/2020
**Signature of Reporting PersonDate

Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arch Therapeutics (QB) Charts.
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arch Therapeutics (QB) Charts.